LMAT vs MDT: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

MDT is the larger of the two ($129.16B market cap): the incumbent the market prices for continued execution (15.76x forward earnings, beta 0.57). LMAT is the smaller challenger ($1.81B), actually pricier on forward earnings (25.12x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

LMAT vs MDT: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricLMATMDTWhat it tells you
Market cap$1.81B$129.16BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E25.1215.76Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E28.7724.81Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.490.57Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range2% of range84% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book4.192.57How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: MDT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how LMAT and MDT affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LMAT and MDT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LMAT and MDT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does LeMaitre Vascular (LMAT) do?

LeMaitre Vascular, founded in 1983 by vascular surgeon George LeMaitre, sells the unglamorous hardware of open vascular surgery: biologic patches, bovine carotid artery grafts sold as Artegraft, human vascular and cardiac allografts, carotid shunts, valvulotomes, embolectomy catheters and synthetic grafts. Roughly 163 direct sales representatives call on vascular surgeons in hospitals, which is the whole point of the model. Individual products are small line items with low average selling prices, too minor for a Medtronic or a Boston Scientific to defend aggressively, so LeMaitre buys niche lines (Restore Flow allografts in 2016 for ~$14M, Artegraft in 2020 for ~$90M), pushes them through its own rep force, and raises prices steadily.

Full LMAT guide

What does Medtronic (MDT) do?

Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans three main areas after October 2026: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), and Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform). Its former Diabetes unit (insulin pumps and continuous glucose monitoring) was carved out as MiniMed, which listed on Nasdaq under MMED; on October 15, 2026 Medtronic exchanged its remaining 252.8 million MiniMed shares for Medtronic shares in an exchange offer that was 5.4 times subscribed, so it no longer owns any of MiniMed. The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics, with trailing revenue of about $37.5 billion as of October 2026.

Full MDT guide

LMAT vs MDT: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • LMAT drivers: Price, not volume, is the growth engine; Artegraft going international.
  • MDT drivers: Diversified device portfolio; Innovation pipeline and new product cycles.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026. For MDT, medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences.

LMAT or MDT: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick LMAT if you believe its drivers more; MDT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LMAT and MDT guides.

LMAT vs MDT: the full fundamentals

LMAT. At $81.89 a share on October 16, 2026 and a ~$1.87B market value, LMAT carries about 7.1 times trailing sales and roughly 6.4 times sales net of its ~$204M net cash position, with a trailing P/E near 29 and a forward P/E near 26. Those are software-adjacent multiples on a $262M revenue base, sustained by 72% gross margins and a two-decade record of annual price increases rather than by growth (organic growth is guided to ~11%). The de-rating from a ~$118 high to within a few dollars of the 52-week low of ~$78.22 happened on a ~$1.1M revenue miss, an EPS miss and a one-point cut to the organic target, which is a measure of how tightly the valuation was tied to the pricing story holding. Seven covering analysts carry a mean target near $107.

MDT. At about $95 on October 16, 2026, Medtronic trades near 15 times forward earnings, a moderate multiple next to faster-growing medtech peers, while the GAAP trailing P/E of about 23x includes acquisition amortization. The 25 analysts tracked by Yahoo Finance hold a mean target near $104. The next report, expected around November 17, 2026, will be the first read on the company after the MiniMed exit, with consensus at about $1.33 of EPS on $9.5 billion of revenue.

Headline figures (approximate, October 2026): LMAT shows revenue (ttm) ~$262M, up ~10% year over year in Q2 2026, q2 2026 sales ~$70.4M, ~10% organic (~7% price, ~3% volume), q2 2026 eps vs estimate ~$0.74 vs ~$0.81 consensus, gross / operating margin (ttm) ~71.9% / ~29%; MDT shows revenue (ttm) ~$37.5 billion, up ~14% year over year in the July 2026 quarter, margins ~65% gross, ~19% operating, ~14% net, net income (ttm) ~$5.2 billion, eps ~$4.07 GAAP trailing; ~$6.41 forward estimate.

The bottom line: LMAT vs MDT

LMAT and MDT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LMAT and MDT exposure against your real portfolio. It is not an investment adviser.

Wondering how LMAT or MDT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about LeMaitre Vascular

Ask Walnut's AI anything about LMAT and see how it fits what you own.

FAQ

What is the difference between LMAT and MDT?

+

LeMaitre Vascular, founded in 1983 by vascular surgeon George LeMaitre, sells the unglamorous hardware of open vascular surgery: biologic patches, bovine carotid artery grafts sold as Artegraft, human vascular and cardiac allografts, carotid shunts, valvulotomes, embolectomy catheters and synthetic grafts. Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is LMAT or MDT the better stock?

+

Neither is universally better. MDT is the larger incumbent; LMAT is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, LMAT or MDT?

+

On forward P/E (as of November 2026), LMAT trades at 25.12x and MDT at 15.76x, so MDT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both LMAT and MDT?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of LMAT vs MDT?

+

LMAT: Cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026. The North Brunswick, New Jersey facility, where the Artegraft graft that now carries ~21% of sales is processed, received additional FDA quality-system observations on June 25, 2026, with a company response filed July 16; an escalation there would reach a large share of revenue. Separately, an FDA pre-submission indicated a clinical trial is likely to be required for the QuickStitch product, on timelines measured in years, and catheter sales fell ~11% against a prior-year period inflated by post-recall stocking orders. Currency, Middle East export disruption and the tissue constraint each accounted for roughly a third of the Q2 revenue shortfall and are expected to persist through the second half. The convertible notes convert near ~$119 to ~$120 per share, which caps upside participation with dilution above that level; as of the latest filings reviewed for this page no filed securities class action, restatement or going-concern matter appears in the company's filings, and the stock's ~28 times guided 2026 earnings (about 26 times 2027 estimates) leaves limited room if pricing power narrows. The September quarter is also a seasonally soft comparison: consensus of ~$0.69 EPS for the November 4 report is below the ~$0.75 of the year-earlier quarter, so a second consecutive miss would land on a stock that has already de-rated. MDT: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. The Hugo robotic platform faces an entrenched Intuitive Surgical. The MiniMed separation removes diabetes but adds near-term noise: reported results, guidance and comparisons will shift as the unit leaves the numbers, and analysts expect EPS of about $1.33 for the quarter ending October 2026, slightly below the year-earlier level. Device companies face reimbursement pressure, hospital budget constraints, FDA approval and recall risk, and litigation exposure. A large international footprint brings currency headwinds, and debt stood near $28 billion against about $8.8 billion of cash as of October 2026. The stock is roughly flat over the past year despite faster sales growth. New-product execution, pipeline timing, and the ability to sustain organic growth remain the key swing factors for the investment case.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell LMAT or MDT; figures are approximate and dated (as of November 2026). Verify current data before investing.